This is the authors' abstract. We don't add key points for this paper.
Kerman et al. and Matas and Sutherland have raised the possibility of performing cadaver donor renal transplantation before completion of a donor/recipient crossmatch, with the aim of minimizing donor kidney cold storage time and with a concomitant increase in transplant function. Both articles stress that proceeding to transplantation in the absence of a crossmatch might be strictly limited to carefully selected cases, in which, by antibody screening performed on multiple samples taken over an extended time, the recipient has been shown to be nonreactive with all cells in a screening panel. We concur with these views and speculate on extending the number of possible opportunities of omitting a pre-transplant cross-match by precise definition of recipient sensitization to HLA specificities and by careful matching for HLA specificities between the donor and recipient. There is increasing and conclusive evidence that recipient sensitization to HLA specificities is the only clinically relevant cause of a positive crossmatch (1). Many kidney transplants have been performed with successful outcome when a crossmatch is positive only because of the presence of immunoglobulin M (IgM) antibodies without specificity for HLA, and which react with the patients own lymphocytes in a cytotoxicity assay (2). Some authors have suggested that serum samples collected remotely from the day of the transplant, and giving a positive crossmatch, have no clinical relevance (3). There is, however, growing consensus that immediate pretransplant and historic serum samples with reactivity for HLA specificities and both IgG and IgM isotypes are harmful to the transplanted kidney. The logical extension of these observations is that whenever the cause of a positive crossmatch is clearly sensitization to HLA, transplantation should not proceed. In contrast, when a positive crossmatch is caused exclusively by antibodies without specificity for HLA, is it acceptable for transplantation to proceed? The HLA specificities to which a potential recipient is sensitized, detected both immediately before the transplant and historically, should, therefore, be clearly identified, and when those specificities are present in a donor kidney, transplantation should be deferred. This approach is aided by recent advances in technology for identifying patient sensitization to HLA specificities. In Europe, but not in North America, it has always been policy to allocate cadaver donor kidneys on the basis of minimizing HLA mismatches between the donor and recipient to achieve better long-term outcomes (4). In the UK in July 1998, this policy was revised with HLA matching receiving increased priority. Since that time, 16% of kidney transplants in the UK were 0 HLA -A, -B, -DR mismatches and 45% were mismatched for only 1 or 2 -A and/or -B mismatches combined with 0 -DR mismatches. Taking together the accurate definition of patient sensitization to HLA and the low degree of HLA mismatching, the opportunities for proceeding to kidney transplantation without an immediate pretransplant crossmatch are increasing. To move to transplantation in the absence of a crossmatch requires significant input from the supporting histocompatibility laboratory. First, an experienced histocompatibility scientist must assess the HLA mismatch of the proposed transplant, in particular to establish the accuracy of the donor HLA phenotype. It is likely that HLA-Cw and -DQ typing must be available, because patients may be sensitized to specificities encoded at these loci. In addition, some might also consider HLA-DP mismatching relevant (5). Second, the patient’s own antibody screening profile must be carefully reviewed, together with details of the potential priming stimulus (e.g., pregnancies, blood transfusions) to reveal HLA-specific sensitization and to rule out unacceptable donor HLA mismatches. For patients with multispecific antibodies, possible crossreactivity with mismatched donor HLA specificities should also be considered. The technique used in screening the patient serum samples, must also be considered. Having reached a view, the histocompatibility expert must converse with the transplant surgeon so that any relevant risk factors can be discussed. For example, a patient with multispecific HLA sensitization and previous failed transplants, may not be a suitable candidate for transplantation without a pre-operative crossmatch, if the proposed transplant involves an HLA mismatched donor, even in the absence of known sensitization to the mismatched specificities. If a transplant does proceed in the absence of a pre-transplant crossmatch, should a crossmatch be done concurrently with the transplant or retrospectively? It would be advisable for each unit to formulate its own policy, but take into account the potential difficulties that might arise. Given recent advances in technology of patient antibody screening and HLA typing, we suggest it is opportune to consider, in strictly defined cases, proceeding with cadaver donor kidney transplantation in the absence of a pre-transplant crossmatch. Philip A. Dyer1 Craig J. Taylor
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dyer et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: